Charles River Laboratories (CRL) and Medigen Vaccine Biologics Corp. (MVC) have entered a strategic partnership aimed at enhancing vaccine development programs. This collaboration focuses on the characterization and validation of the virus seed bank for MVC’s innovative next-generation multivalent enterovirus vaccine. By employing advanced analytical techniques, particularly Next-Generation Sequencing (NGS), Charles River will play a crucial role in supporting the Chemistry, Manufacturing, and Controls (CMC) activities essential for the vaccine’s progression.
Shared Commitment to Quality and Innovation
Both CRL and MVC share a strong commitment to high-quality development and scientific rigor. Their collaboration is designed to align closely with global regulatory standards, facilitating the efficient advancement of MVC’s vaccine program. MVC has already established its credentials in vaccine development with its proprietary Envacgen Enterovirus 71 Vaccine, which has received approval in Taiwan and Vietnam. This success serves as a foundation for MVC’s ongoing efforts to develop a next-generation multivalent enterovirus vaccine.
Leveraging Expertise for Acceleration
In selecting Charles River as its strategic partner, MVC aims to leverage the extensive global expertise that CRL brings in areas such as virology, biologics testing, and regulatory science. Kerstin Dolph, corporate senior vice president at Charles River, expressed enthusiasm about the partnership, emphasizing the collaborative potential of combining CRL’s testing and NGS capabilities with MVC’s vaccine research expertise. This partnership aims to generate robust data necessary for Investigational New Drug (IND) applications and to speed up clinical development.
Comprehensive Development Approach
The collaboration aims to combine CRL’s leading global biologics testing and non-clinical development capabilities with MVC’s established research prowess. This partnership focuses on enhancing global regulatory readiness and supporting IND-enabling non-clinical studies. By working together, the two companies hope to facilitate the development of high-quality vaccines that can effectively address global infectious diseases and unmet medical needs.
Next-Generation Sequencing: A Game Changer
Next-Generation Sequencing (NGS) is at the forefront of revolutionizing advanced therapeutics by providing a more efficient method for genetic analysis and pathogen detection. With its high throughput, scalability, and speed, NGS ensures that high-quality products reach patients more quickly. Charles River’s CGMP NGS testing services are designed to accelerate development timelines while adhering to stringent safety and regulatory standards, ensuring accuracy and reliability.
Strategic Acquisitions to Enhance Capabilities
To further bolster its NGS capabilities, Charles River has acquired Pathoquest, a leader in NGS solutions specifically tailored for in vitro characterization and quality control testing of biopharmaceutical products. This acquisition allows Charles River to offer even faster and more sophisticated sequencing-based testing, enhancing the value provided to clients throughout the development pipeline.
A Comprehensive Partner for Biopharmaceutical Development
Charles River’s Biologics Testing Solutions portfolio enables biopharmaceutical developers to navigate the complexities of drug development with confidence. As a global partner, CRL combines reliability with integrated GMP-compliant testing capabilities and digital tools, reducing risks and accelerating timelines. This comprehensive approach supports regulatory success across diverse biological modalities, ensuring that clients can advance life-changing therapies with greater certainty.
A Focus on Public Health
Founded in 2012, MVC is dedicated to combating infectious diseases through innovative vaccine development and mass production. Utilizing advanced cell-culture technology and a GMP-certified biopharmaceutical facility, MVC has demonstrated its robust R&D capabilities, notably serving as the only domestic manufacturer to receive Emergency Use Authorization (EUA) in Taiwan during the COVID-19 pandemic.
Looking Ahead
The collaboration between Charles River and Medigen Vaccine Biologics signifies a promising step forward in vaccine development, marrying innovative technology with strategic expertise. As they work together to develop the next-generation multivalent enterovirus vaccine, they are not only addressing current health challenges but are also laying the groundwork for future vaccine development initiatives.
In conclusion, the partnership stands as a testament to the power of collaboration in the life sciences sector. By combining their strengths, CRL and MVC are poised to tackle pressing global health issues while ensuring that innovative vaccines meet the highest standards of quality and efficacy.
- Collaboration focuses on next-generation multivalent enterovirus vaccine.
- Charles River employs advanced NGS technology for vaccine development.
- Both companies aim for alignment with global regulatory standards.
- MVC has a proven track record with their Envacgen Enterovirus 71 Vaccine.
- NGS enhances the speed and quality of vaccine characterization.
- Strategic acquisition of Pathoquest bolsters Charles River’s testing capabilities.
Read more → pharmabiz.com